Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S in Advanced Solid Tumors
NCT05579366Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Dec 2022
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of rinatabart sesutecan in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), endometrial cancer (EC), non-small cell lung cancer (NSCLC), sponsored by Genmab. Started Dec 2022; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05579366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579366.